

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-003112/21/2005

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/032,214
		Filing Date	December 20, 2001
		First Named Inventor	Juha Punnonen, et al.
		Group Art Unit	1644
		Examiner Name	Ilia I. Ouspenski
		Attorney Docket Number	0169.410US

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
I.O.	1	5,718,883		Harlan et al.	02-17-1998
	2	5,738,852		Robinson et al.	04-14-1998
	3	5,858,776		Ostrand-Rosenberg et al.	01-12-1999
	4	6,045,802		Schlom et al.	04-04-2000
	5	6,149,905		Ostrand-Rosenberg et al.	11-21-2000

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	6	WO	94/24267		Robinson, William S.	10-27-1994		
	7	WO	95/23859		Brigham/Women's Hosp.; Dana-Farber Cancer Inst.	09-08-1995		
	8	WO	95/03408		Dana-Farber Cancer Inst.	02-02-1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers).			
	9	He, X-S. et al., "Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen," Proc. Natl. Acad. Sci. USA 93:7274-7278 (1996)			
	10	Kuchroo, V.K. et al., "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707-718 (1995)			
	11	Metzler, W., et al., "Solution Structure of Human CTLA-4 and Delineation of a CD80/CD86 Binding Site Conserved in CD28," Nature Structural Biology 4(7):527-531 (July 1997)			
	12	Rennert, P. et al., "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion," International Immunology 9(6):805-813 (1997)			
	13	Wu, Y., "CTLA-4-B7 Interaction Is Sufficient to Costimulate T Cell Clonal Expansion," J. Exp. Med. 185(7):1327-1335 (1997)			
	14	Doty, R. et al., "Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation," Journal of Immunology 157:3270-3279 (1996)			
	15	Linsley, P.S. et al., "Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors," Immunity 1:793-801 (December 1994)			
	16	Linsley, P.S. et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," J. Exp. Med. 173:721-730 (March 1991)			
	17	Sturmhoefel, K., "Potent activity of soluble B7-1gG fusion proteins in therapy of established tumors and as vaccine adjuvant," Cancer Research 59:4964-4972 (October 1999)			
I.O.	18	Swiniarski, H. et al., "Immune response enhancement by <i>in vivo</i> administration of B7.21g, a soluble costimulatory protein," Clinical Immunology 92(3):235-245 (1999)			

Examiner Signature	<i>Ilia Ouspenski</i>	Date Considered	12/21/2005
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.